Dynorphin A
The native 17-residue product of prodynorphin and the principal endogenous agonist of the kappa-opioid receptor, whose 1-13 fragment was tested in small human studies of opioid withdrawal and cancer pain, with no approved product anywhere.
Also referenced as: Dynorphin, Dynorphin A (1-17), Dynorphin A 1-17, Dyn A
Also appears in: Hormone
Public product evidence No certificate records are bound to a tracked Dynorphin A product page A record counts here only when a vendor publishes a certificate against one of its own tracked Dynorphin A product pages. Other certificates naming this compound may still exist — search the wider certificate database.This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Neuroprotection. Also surfaces under Hormone for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
Dynorphin, Dynorphin A (1-17), Dynorphin A 1-17, Dyn A
No FDA label signal · 14 trials · 1000 PubMed results
Dynorphin A has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Dynorphin A has 1 name-matched clinical trial (highest phase: Phase 2) and 1000 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Dynorphin A?
Dynorphin A is a native 17-amino-acid opioid peptide with the sequence Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln, determined from porcine pituitary extract by Avram Goldstein’s group and published in 1981 (Goldstein et al., Proceedings of the National Academy of Sciences, 1981;78(11):7219-7223). Its first five residues are the pentapeptide leu-enkephalin, and the eight-residue basic extension that follows converts a weak enkephalin into a highly potent opioid: the 13-residue fragment first reported in 1979 was about 700 times more potent than leu-enkephalin in the guinea pig ileum preparation (Goldstein et al., Proceedings of the National Academy of Sciences, 1979;76(12):6666-6670).
In humans the peptide is encoded within PDYN, the prodynorphin gene, whose 254-residue precursor carries dynorphin A at residues 207 through 223 with a sequence identical to the porcine peptide. Prodynorphin is the third classical opioid precursor family, alongside proopiomelanocortin, which yields beta-endorphin, and proenkephalin, which yields met-enkephalin and leu-enkephalin. It also releases alpha- and beta-neoendorphin, dynorphin B, leumorphin, and the 32-residue big dynorphin joining dynorphin A to dynorphin B.
Dynorphin A has never been an approved medicine in any country. It serves as a research reagent and reference peptide in receptor pharmacology, and the 1-13 fragment, not the full peptide, was used in the small human studies.
How it works
- Selective agonist at the kappa-opioid receptor. In the guinea pig ileum myenteric plexus preparation, dynorphin A 1-13 and the prototypical kappa agonist ethylketocyclazocine were equally insensitive to naloxone antagonism and showed selective cross protection in receptor inactivation experiments, and in guinea pig brain membranes both were more potent at displacing labeled ethylketocyclazocine than at displacing typical mu and delta ligands, identifying the dynorphin receptor as the kappa receptor (Chavkin et al., Science, 1982;215(4531):413-415). A cryo-electron microscopy structure of the human kappa-opioid receptor with Gi and dynorphin A has since resolved how the endogenous agonist engages the receptor (Chen et al., Protein & Cell, 2023;14(6):464-468).
- One of several peptides from a single precursor, with graded receptor behavior. The precursor was cloned from porcine hypothalamic messenger RNA in 1982 and shown to contain beta-neoendorphin, dynorphin and a carboxyl-extended leucine-enkephalin sequence, each bounded by Lys-Arg processing sites (Kakidani et al., Nature, 1982;298(5871):245-249). Dynorphin A and big dynorphin bind the human kappa receptor with similar affinity, higher than that of dynorphin B, while dynorphin A is the more kappa-selective against mu, delta and nociceptin receptors and big dynorphin the more potent activator of G proteins (Merg et al., Journal of Neurochemistry, 2006;97(1):292-301).
- Rapid biotransformation into opioid and non-opioid fragments. Rat brain membranes degrade the peptide quickly, pointing to a membrane-bound degradative enzyme (Goldstein et al., Proceedings of the National Academy of Sciences, 1979;76(12):6666-6670). In human blood, dynorphin A 1-13 is accompanied by the metabolites dynorphin A 2-13, 1-12 and 2-12, which can be measured only with peptidase-blocking sample handling (Müller et al., Journal of Pharmaceutical and Biomedical Analysis, 1997;16(1):101-109). Enzymatic instability remains the principal obstacle to developing the peptide or its fragments as therapeutics (Ballouze et al., Future Medicinal Chemistry, 2023;15(9):791-808).
- Non-opioid, glutamate-linked actions distinct from kappa signaling. Intrathecal dynorphin A 1-17 and the opioid-inactive fragment dynorphin A 2-17 both produce hindlimb motor dysfunction in rats, the full-length peptide about 2.5 times more potently; the kappa-selective antagonist nor-binaltorphimine markedly attenuates the effect of dynorphin A 1-17 at lower doses, less so at higher doses, and does not modify that of dynorphin A 2-17 (Faden, Annals of Neurology, 1990;27(1):67-74). Competitive and non-competitive NMDA antagonists each reduce the paralysis and mortality caused by both peptides, implicating the NMDA receptor (Bakshi and Faden, Brain Research, 1990;507(1):1-5), and a truncated form of dynorphin A 2-17 that binds bradykinin receptors facilitates spinal wide-dynamic-range neuron responses in nerve-injured but not naive rats (Bannister et al., Neuropharmacology, 2014;85:375-383).
Research status
Human studies in opioid withdrawal. The clinical record is small and belongs almost entirely to one group. In the first report, dynorphin A 1-13 at 60 µg/kg of body weight suppressed heroin withdrawal symptoms in 12 patients, with a strong placebo response to saline that the authors judged not to have altered the result; three of the 12 reported mild effects described as feeling warm, dizziness and precordial formication (Wen and Ho, European Journal of Pharmacology, 1982;82(3-4):183-186). A blinded follow-up compared beta-endorphin, dynorphin A 1-13, dynorphin A 1-10 amide, alpha-neoendorphin and a stabilized enkephalin analog in groups of six patients at the same bolus dose: all treatments including saline lowered withdrawal scores, only beta-endorphin, the enkephalin analog and dynorphin A 1-13 did so significantly, and dynorphin A 1-13 relieved symptoms for an average of 46 minutes (Wen et al., European Journal of Pharmacology, 1984;100(2):155-162).
Human study in cancer pain. Dynorphin A 1-13 and dynorphin A 1-10 were injected intrathecally into six patients with terminal cancer at 7.5, 15, 30 and 60 µg. Both relieved pain compared with saline, with relief lasting more than 4 hours on average at 15 µg and above, but doubling the dose produced no proportional increase in response, which the authors attributed to possible tolerance (Wen et al., Peptides, 1987;8(1):191-193).
Human pharmacokinetics. The largest rigorous human exposure study infused dynorphin A 1-13 over 10 minutes in 20 volunteers, 10 at 250 µg/kg and 10 at 1,000 µg/kg, four of each 10 on long-term opioid therapy. Disposition of dynorphin immunoreactivity was linear and fitted a three-compartment model, concomitant opioid therapy changed neither the pharmacokinetics nor the adverse-effect profile, and the peptide was very rapidly metabolized; tachycardia and flushing were common and rose in incidence with dose (Gambús et al., Clinical Pharmacology and Therapeutics, 1998;64(1):27-38).
The one registered trial. ClinicalTrials.gov lists a single interventional study of the peptide: NCT00000244, a University of Minnesota phase 2 study of dynorphin 1-13 in opioid-related disorders and substance withdrawal syndrome, which began in August 1994 and reached actual primary completion in March 1997. The registry records the study as completed with no posted results. Supporting toxicology from the same institution found no behavioral or histologic abnormality in rats given dynorphin A 1-13 intravenously at 5 mg/kg or 40 mg/kg per day, while all six animals given 100 mg/kg convulsed and died within minutes; the authors concluded that the spinal necrosis and hindlimb paralysis seen after intrathecal administration is a local effect (Pentel et al., Pharmacology, Biochemistry, and Behavior, 1995;51(2-3):387-390).
Stabilized analogs. One analog program reached repeat dosing in humans: E2078, a metabolically stable dynorphin A analog, was given to 21 healthy subjects. Single intramuscular doses and repeated dosing produced a dose-dependent water diuresis, with urine osmolality falling 17 to 27%, free-water clearance turning positive and plasma antidiuretic hormone falling; the effect attenuated after the first repeated dose (Ohnishi et al., Journal of Pharmacology and Experimental Therapeutics, 1994;270(1):342-347). No approved product followed.
Stress, dysphoria and addiction circuitry. Preclinical work treats the dynorphin-kappa system as the substrate of aversion rather than a drug candidate. Repeated forced swim and inescapable footshock produced aversive behavior that a kappa antagonist blocked and that was absent in mice lacking dynorphin, and corticotropin-releasing factor produced place aversion that dynorphin gene deletion or kappa antagonism likewise blocked (Land et al., Journal of Neuroscience, 2008;28(2):407-414). That result pointed drug development toward kappa antagonists rather than toward dynorphin itself.
Human neurodegenerative genetics. Missense mutations in PDYN cause spinocerebellar ataxia type 23 in four Dutch families with progressive gait and limb ataxia. Three of the four mutations fall inside dynorphin A, two caused excessive peptide generation in a cellular model and two produced toxicity in cultured striatal neurons above that of the wild-type peptide; PDYN mutations account for roughly 0.5% of ataxia families in the Netherlands (Bakalkin et al., American Journal of Human Genetics, 2010;87(5):593-603). A mouse model carrying the R212W mutation developed elevated mutant dynorphin A, Purkinje cell loss and progressive motor dysfunction (Smeets et al., Brain, 2015;138(Pt 9):2537-2552), and a structural study linked the mutations to loss of the peptide’s N-terminal helix, reduced kappa-receptor affinity and NMDA-mediated excitotoxicity (Smeets et al., Human Molecular Genetics, 2016;25(13):2728-2737).
Current state. As of November 2026, Drugs@FDA lists no application for dynorphin A, DailyMed lists no labeling, and ClinicalTrials.gov lists no recruiting or planned interventional study of the peptide or its fragments. Clinical kappa-receptor pharmacology has moved to engineered agents such as difelikefalin, approved as Korsuva under NDA 214916 on August 23, 2021, with a generic approved under ANDA 220919 on August 31, 2026.
Common dosage forms
- No approved presentation. No dynorphin A product is licensed in the US or any other jurisdiction, so no vial, ampoule, pen, tablet or kit presentation exists.
- Historical investigational presentations. The human studies used sterile solutions of dynorphin A 1-13 or 1-10 given by clinicians at the investigating centers and never supplied as a commercial product.
- Research-reagent presentation. Dynorphin A and its 1-13 and 1-8 fragments are supplied as lyophilized synthetic powders in sealed vials for laboratory use.
Key considerations
- Regulatory status. The Research Market status reflects the absence of any FDA-approved dynorphin A product and the absence of any registered, active human development program. The only interventional trial in the registry, NCT00000244, completed in March 1997 without posted results, and the one analog program to reach repeat human dosing, E2078, produced no approved product.
- The human record is small, dated and largely uncontrolled. The published efficacy reports enrolled six to 12 patients per treatment group, the largest rigorous human study measured disposition and adverse effects rather than efficacy, and the registered phase 2 trial has no public results. No adequately powered efficacy trial exists in any indication.
- Kappa activation carries dysphoria and psychotomimetic effects. In male subjects, the opiate-active isomer of the benzomorphan kappa agonist MR 2033, which is inactive at sigma-phencyclidine receptors, produced dose-dependent dysphoric and psychotomimetic effects that naloxone antagonized, establishing those effects as kappa-mediated (Pfeiffer et al., Science, 1986;233(4765):774-776). A centrally acting kappa agonist is therefore expected to be aversive rather than pleasant, which is why clinical interest shifted to kappa antagonists.
- Non-opioid neurotoxicity is a documented property of this peptide. Intrathecal administration causes hindlimb paralysis and spinal cord damage in rats through an NMDA-linked mechanism that opioid antagonists do not fully reverse, dynorphin antiserum improves outcome after experimental spinal cord trauma, and mutant forms of the peptide kill neurons in spinocerebellar ataxia type 23. Placement under neuroprotection reflects the nervous-system research setting rather than a demonstrated protective effect.
- Naming. Dynorphin A, dynorphin A 1-17 and the historic name dynorphin denote the same 17-residue peptide, while dynorphin A 1-13, 1-10 and 1-8 are shorter fragments of it and big dynorphin is the 32-residue peptide containing dynorphin A and dynorphin B. Dynorphin B, leumorphin and the neoendorphins are separate precursor products, and E2078 and difelikefalin are distinct synthetic molecules rather than aliases.